Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Recombinant BNP on Heart and Renal Function in Acute Heart Failure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Dr. Fang Yuan, Shanghai Chest Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Dr. Fang Yuan, Shanghai Chest Hospital Identifier:
First received: June 19, 2012
Last updated: August 5, 2012
Last verified: August 2012
The purpose of this study is to evaluate the efficacy and safety of recombinant human B-type natriuretic peptide (rhBNP) on heart and renal function in patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI).

Condition Intervention Phase
Acute Heart Failure
Acute Renal Failure
Drug: rhBNP
Drug: standard of care
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Recombinant BNP on Heart and Renal Function in Acute Decompensated Heart Failure Patients With Acute Renal Injury

Resource links provided by NLM:

Further study details as provided by Dr. Fang Yuan, Shanghai Chest Hospital:

Primary Outcome Measures:
  • left ventricular systolic function [ Time Frame: 90 days ]

Secondary Outcome Measures:
  • serum creatinine [ Time Frame: 90 days ]

Estimated Enrollment: 100
Study Start Date: July 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rhBNP treated
standard of care with rhBNP
Drug: rhBNP
intravenous administration of rhBNP 0.01 µg/kg/min
Active Comparator: standard of care
standard of care
Drug: standard of care
standard of care for heart failure

Detailed Description:

Patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI) will be randomized to receive standard of care with or without additional rhBNP.

Clinical heart function, LVEF, SCr, GFR and other laboratory parameters will be evaluated.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • acute heart failure with acute renal injury

Exclusion Criteria:

  • not tolerate to rhBNP
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01625403

Contact: Fang Yuan

China, Shanghai
Shanghai Chest Hospital Recruiting
Shanghai, Shanghai, China, 200030
Contact: Fang Yuan   
Principal Investigator: Fang Yuan         
Sponsors and Collaborators
Shanghai Chest Hospital
Principal Investigator: Fang Yuan Shanghai Chest Hospital
  More Information

Responsible Party: Dr. Fang Yuan, Dr., Shanghai Chest Hospital Identifier: NCT01625403     History of Changes
Other Study ID Numbers: SHCHESTCCU01
Study First Received: June 19, 2012
Last Updated: August 5, 2012

Keywords provided by Dr. Fang Yuan, Shanghai Chest Hospital:
Recombinant BNP
Acute decompensated heart failure
Acute renal injury
Heart function
Renal function

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Acute Kidney Injury
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases processed this record on May 25, 2017